Introduction Executive Summary Potassium channel antagonists: Overview • Structure • Mechanism of Action Pipeline Therapeutics • Comparative Analysis Therapeutic Assessment • Assessment by Product Type • Assessment by Stage and Product Type • Assessment by Route of Administration • Assessment by Stage and Route of Administration • Assessment by Molecule Type • Assessment by Stage and Molecule Type Potassium channel antagonists – DelveInsight’s Analytical Perspective In-depth Commercial Assessment • Potassium channel antagonists companies’ collaborations, Licensing, Acquisition -Deal Value Trends Potassium channel antagonists Collaboration Deals • Company-Company Collaborations (Licensing / Partnering) Analysis • Company-University Collaborations (Licensing / Partnering) Analysis Late Stage Products (Phase III) • Comparative Analysis Amifampridine: BioMarin • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Mid Stage Products (Phase II) • Comparative Analysis Sleep apnoea therapeutic: Bayer • Product Description • Research and Development Drug profiles in the detailed report….. Pre-clinical and Discovery Stage Products • Comparative Analysis Research programme Kv1.3 potassium channel inhibitors: 4SC • Product Description • Research and Development • Product Development Activities Drug profiles in the detailed report….. Inactive Products • Comparative Analysis Potassium channel antagonists Key Companies Potassium channel antagonists Key Products Potassium channel antagonists- Unmet Needs Potassium channel antagonists- Market Drivers and Barriers Potassium channel antagonists- Future Perspectives and Conclusion Potassium channel antagonists Analyst Views Potassium channel antagonists Key Companies Appendix

Table 1 Total Products for Potassium channel antagonists Table 2 Late Stage Products Table 3 Mid Stage Products Table 4 Early Stage Products Table 5 Pre-clinical & Discovery Stage Products Table 6 Assessment by Product Type Table 7 Assessment by Stage and Product Type Table 8 Assessment by Route of Administration Table 9 Assessment by Stage and Route of Administration Table 10 Assessment by Molecule Type Table 11 Assessment by Stage and Molecule Type Table 12 Inactive Products

• Bayer • 4SC • selection • Boston Pharmaceuticals • Pierre Fabre • Catalyst pharma